This Article Full Text Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Madrid, M. I. Articles by Fenoy, F. J. Search for Related Content PubMed PubMed Citation Articles by Madrid, M. I. Articles by Fenoy, F. J. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB NITRIC OXIDE

(Hypertension. 1997;30:1175-1182.)
© 1997 American Heart Association, Inc.

Articles

Interactions Between Nitric Oxide and Angiotensin II on Renal Cortical and Papillary Blood Flow

María Isabel Madrid; Miguel García-Salom; Jerónimo Tornel; Marc de Gasparo; Francisco J. Fenoy

From the Departamento de Fisiología y Farmacología (M.I.M., M.G.-S., J.T., F.J.R.), Facultad de Medicina, 30100-Murcia, Spain, and Novartis Ltd (M. de G.), CH-4002 Basel, Switzerland.

Correspondence to Francisco J. Fenoy, Departamento de Fisiología y Farmacología, Facultad de Medicina, 30100-Murcia, Spain. E-mail fjfenoy{at}fcu.um.es

Abstract This study examined the role of angiotensin II (Ang II) on the effects of nitric oxide (NO) synthesis blockade on renal cortical and papillary blood flow in innervated and denervated kidneys of volume-expanded Munich-Wistar rats with hormonal influences on the kidney that were held constant by intravenous infusion. Cortical (CBF) and papillary (PBF) blood flow were measured by laser-Doppler flowmetry. A low dose of N-nitro-L-arginine methyl ester (L-NAME, 3.7 nmol · kg^-1 · min^-1) reduced CBF only in innervated kidneys, and this effect was abolished by subsequent administration of valsartan (an AT₁ antagonist). L-NAME 3.7 nmol · kg^-1 · min^-1 improved PBF autoregulation by lowering PBF to the range of 100 to 140 mm Hg of perfusion pressure, and this effect was attenuated or abolished by valsartan in innervated and denervated kidneys, respectively. These results indicate that the cortical and medullary vasoconstriction induced by a low dose of L-NAME are caused by potentiation of the vasoconstrictor influence of renal sympathetic nerves and Ang II. A higher dose of L-NAME (37 nmol · kg^-1 · min^-1) lowered CBF and PBF in both innervated and denervated kidneys. This effect of L-NAME on the cortical circulation was abolished by valsartan, but this AT₁ antagonist had no effect on the medullary vasoconstriction produced by NO synthesis blockade. Therefore, a higher dose of L-NAME induces a renal cortical vasoconstriction through potentiation of the renin-angiotensin system, whereas the fall of PBF seen after L-NAME 37 nmol · kg^-1 · min^-1 seems to be caused primarily by NO suppression. This Ang II potentiation produced by L-NAME in the renal cortex seems to be mediated by AT₁ receptors, because it was unaffected by PD123319 (an AT₂ antagonist). The results of the present study indicate that NO is an important modulator of the vasoconstrictor influence of Ang II in the renal cortical circulation of the rat. However, although there are some interactions between NO and renal nerves and Ang II on the medullary circulation, the renal medullary vasoconstriction produced by L-NAME appears to be caused primarily by NO suppression, with little influence of the renal vasoconstrictor systems.

Key Words: nitric oxide • kidney • renal hemodynamics • laser-Doppler flowmetry

This article has been cited by other articles:

				N. Toda, K. Ayajiki, and T. Okamura Interaction of Endothelial Nitric Oxide and Angiotensin in the Circulation Pharmacol. Rev., March 1, 2007; 59(1): 54 - 87. [Abstract] [Full Text] [PDF]

				M. Obst, V. Gross, J. Janke, M. Wellner, W. Schneider, and F. C. Luft Pressure Natriuresis in AT2 Receptor-Deficient Mice with L-NAME Hypertension J. Am. Soc. Nephrol., February 1, 2003; 14(2): 303 - 310. [Abstract] [Full Text] [PDF]

				K. Lopau, L. Hefner, G. Bender, E. Heidbreder, and C. Wanner Haemodynamic effects of valsartan in acute renal ischaemia/reperfusion injury Nephrol. Dial. Transplant., August 1, 2001; 16(8): 1592 - 1597. [Abstract] [Full Text] [PDF]

				L. Raij Workshop: Hypertension and Cardiovascular Risk Factors : Role of the Angiotensin II-Nitric Oxide Interaction Hypertension, February 1, 2001; 37(2): 767 - 773. [Abstract] [Full Text] [PDF]

				J. Tornel, M. I. Madrid, M. Garcia-Salom, K. J. Wirth, and F. J. Fenoy Role of Kinins in the Control of Renal Papillary Blood Flow, Pressure Natriuresis, and Arterial Pressure Circ. Res., March 17, 2000; 86(5): 589 - 595. [Abstract] [Full Text] [PDF]

				I. Hernandez, L. F. Carbonell, T. Quesada, and F. J. Fenoy Role of angiotensin II in modulating the hemodynamic effects of nitric oxide synthesis inhibition Am J Physiol Regulatory Integrative Comp Physiol, July 1, 1999; 277(1): R104 - R111. [Abstract] [Full Text] [PDF]

				B. Braam Renal endothelial and macula densa NOS: integrated response to changes in extracellular fluid volume Am J Physiol Regulatory Integrative Comp Physiol, June 1, 1999; 276(6): R1551 - R1561. [Abstract] [Full Text] [PDF]

				M. Szentivanyi Jr, C. Y. Maeda, and A. W. Cowley Jr Local Renal Medullary L-NAME Infusion Enhances the Effect of Long-Term Angiotensin II Treatment Hypertension, January 1, 1999; 33(1): 440 - 445. [Abstract] [Full Text] [PDF]